Advert - Daiichi Sankyo– Case AUTH/3627/4/22

• Date posted
  16 June 2023
• Sanction
  Advertisement,
• Case number/s
  AUTH/3627/4/22 - Complainant v Daiichi Sankyo

For the omission of safety information in relation to symptoms, which might not be readily recognised by the patient as signs of excessive bleeding, in two Lixiana (edoxaban) patient booklets, Daiichi Sankyo was ruled in breach of the following clauses of the 2021 Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the
pharmaceutical industry
Clause 5.1 - Failing to maintain high standards
Clause 6.1 - Providing misleading information
Clause 6.2 - Misleading impression incapable of substantiation